Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

ClinicalTrials.gov ID: NCT01894516

Public ClinicalTrials.gov record NCT01894516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

* Participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - 50 milligram (mg), 100 mg and 200 mg once daily) or matching placebo for 24 weeks. * During the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects of different doses of GLPG0634 administration on participants' disability, fatigue and quality of life were evaluated.

Study identification

NCT ID
NCT01894516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Enrollment
287 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 7, 2013
Primary completion
Mar 4, 2015
Completion
May 28, 2015
Last update posted
Dec 15, 2020

2013 – 2015

United States locations

U.S. sites
21
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Artho Care, Arthritis Care & Research P.C. Gilbert Arizona
Arizona Arthritis & Rheumatology Research PLLC Mesa Arizona
Arizona Arthritis Rheum Res Phoenix Arizona
Little Rock Diagnostic Clinic Little Rock Arkansas
C.V. Mehta MD Medical Corp. Hemet California
Center for Innovative Therapy Division of Rheumatology, UCSD La Jolla California
Desert Medical Advances Palm Desert California
Infosphere Clinical Research, Inc. West Hills California
Lovelace Scientific Resources Venice Florida
Arthritis Center of North GA Gainesville Georgia
The Arthritis Center Springfield Illinois
Klein and Associates MD Hagerstown Maryland
Private practice Lansing Michigan
Arthritis Center of Reno Reno Nevada
New Jersey Physicians, LLC Clifton New Jersey
Health research of Oklahoma Oklahoma City Oklahoma
Altoona Center Clin Research Duncansville Pennsylvania
Low Country Rheumatology, PA Charleston South Carolina
Arthritis Clinic Jackson Tennessee
Austin Rheumatology Research PA Austin Texas
Pioneer Research Solutions Inc Houston Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01894516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 15, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01894516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →